Showing results (1211-1220 of 1,246) with videos related to
Sort By:
Pageof 125
Nature|November 16, 2007
Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-ASergey Nejentsev, Joanna M M Howson, Neil M Walker, et al.Molecular Pharmaceutics|February 3, 2016
A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory DiseaseManon F Pritchard, Lydia C Powell, Georgina E Menzies, et al.Cell Reports. Medicine|January 14, 2022
The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiotaStephen J Blake, Jane James, Feargal J Ryan, et al.Journal of Hydrometeorology|April 10, 2018
The plumbing of land surface models: is poor performance a result of methodology or data quality?Ned Haughton, Gab Abramowitz, Andy J Pitman, et al.Nature Genetics|October 18, 2005
Population structure, differential bias and genomic control in a large-scale, case-control association studyDavid G Clayton, Neil M Walker, Deborah J Smyth, et al.Environmental Toxicology and Chemistry|July 25, 2013
Cross-species sensitivity to a novel androgen receptor agonist of potential environmental concern, spironolactoneCarlie A LaLone, Daniel L Villeneuve, Jenna E Cavallin, et al.Kidney International|May 16, 2019
Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney diseaseCeri Rowe, Alice J Sitch, Jonathan Barratt, et al.Breast Cancer Research and Treatment|April 26, 2020
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortiumJill R Dietz, Meena S Moran, Steven J Isakoff, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 19, 2013
Postthymic expansion in human CD4 naive T cells defined by expression of functional high-affinity IL-2 receptorsMarcin L Pekalski, Ricardo C Ferreira, Richard M R Coulson, et al.The Lancet. Oncology|December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trialRodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.Pageof 125